Pharmena SA
Pharmena SA operates in the Personal Products industry, focusing on the development, production, and distribution of personal care and household products.
Business. Pharmena SA (PHR.WA) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
20 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJosh Gottheimer — Phreesia, Inc. Common Stock2026-03-05 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — Phreesia, Inc.2023-10-16 · Democrat · NJ · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — Phreesia, Inc.2023-09-15 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — Phreesia, Inc.2021-12-15 · Democrat · NJ · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — Phreesia, Inc.2020-12-21 · Democrat · NJ · Sale · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Pharmena SA (PHR.WA) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Pharmena SA exhibits a strong liquidity position, with a current ratio of 13.97 and cash and equivalents amounting to 22,176,000 PLN, which significantly exceeds its total liabilities of 1,797,000 PLN. The company's debt-to-equity ratio is 0.01, indicating a conservative capital structure with minimal reliance on debt financing. Despite this, the company reported a negative net income of -45,281,000 PLN, which is a significant deviation from typical performance in the Personal Products industry.
The company's profitability metrics are notably weak, with a return on equity of -1.9557 and a return on assets of -1.8149, both of which are far below the industry median for the Personal Products sector. This suggests that Pharmena is underperforming in terms of generating returns for shareholders and utilizing its assets efficiently. Gross profit of 852,000 PLN and operating income of 142,000 PLN are insufficient to offset the company's net loss, indicating potential operational inefficiencies or cost overruns.
Pharmena's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests that the company may have a relatively undiversified business model. This could expose the company to higher risks if demand for its products declines in a specific market or customer base. The lack of detailed segment reporting also limits the ability to assess the performance of individual product lines or geographic regions.
Looking ahead, the company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or outlooks for the current or next fiscal year. The negative net income and weak profitability metrics suggest that the company may face challenges in sustaining growth without significant operational improvements or cost reductions. The absence of a clear growth strategy or capital allocation plan further complicates the assessment of future performance.
Risk factors for Pharmena include the potential for dilution, although the risk is currently assessed as low. The company has not issued additional shares recently, and there are no immediate filing-based liquidity or dilution flags. However, the negative net income and weak returns could pressure the company to raise capital in the future, which may involve issuing new shares and diluting existing shareholders. The company's liquidity position is strong, but the negative free cash flow of -46,418,000 PLN indicates that the company is not generating sufficient cash to fund operations and growth.
Recent events and filings do not provide specific details on strategic initiatives or operational changes, but the company's financial performance suggests that it may be undergoing a period of restructuring or cost optimization. The absence of recent transcripts or detailed disclosures limits the ability to assess the company's strategic direction and management's response to current challenges. Investors should monitor future filings and earnings reports for more insight into the company's financial health and strategic plans.
- Pharmena SA has a strong liquidity position with a current ratio of 13.97 and significant cash reserves.
- The company is underperforming in terms of profitability, with a negative return on equity and return on assets.
- The lack of segment and geographic revenue breakdowns suggests a potentially undiversified business model.
- The company's growth trajectory is uncertain, with no clear forward-looking revenue projections.
- The risk of dilution is currently low, but the negative net income and weak returns could pressure the company to raise capital in the future.
Bull / Bear case
Generated · model-assistedAnalysts project 381.5% upside to a mean price target of 15.12 PLN, signaling strong market confidence in future performance.
Debt-to-equity ratio of 0.01 is significantly lower than the cohort median of 0.14, reflecting a conservative capital structure.
Net income improved by 19.6% year-over-year, demonstrating a positive trajectory in profitability despite recent revenue declines.
Low dilution, liquidity, and credit risk flags suggest a stable financial environment with minimal immediate structural threats.
Net margin of -41.9% places the company in the bottom quartile of its cohort, signaling poor profitability relative to peers.
Return on equity of -1.96% ranks in the bottom quartile, indicating inefficient use of shareholder capital compared to competitors.
Cash conversion ratio of -0.68 is in the bottom quartile, suggesting significant challenges in converting earnings into cash.
In focus — financials by report
Revenue PLN 386.0k, +160,8% YoY; Operating income −29,2% YoY.
- ▍Revenue PLN 386.0k, +160,8% YoY
- ▍Operating income −29,2% YoY
- ▍Net income −15,9% YoY
- ▍Free cash flow −19,6% YoY
- ▍Net margin -181.3%
Revenue PLN 393.0k, +3 830,0% YoY; Operating income +37,2% YoY.
- ▍Revenue PLN 393.0k, +3 830,0% YoY
- ▍Operating income +37,2% YoY
- ▍Net income −300,4% YoY
- ▍Free cash flow −289,9% YoY
- ▍Net margin -124.4%
Revenue PLN 88.0k, −91,8% YoY; Operating income −613,4% YoY.
- ▍Revenue PLN 88.0k, −91,8% YoY
- ▍Operating income −613,4% YoY
- ▍Net income +99,7% YoY
- ▍Free cash flow +99,5% YoY
- ▍Net margin -134.1%
Revenue PLN 22.0k; Operating income -PLN 729.0k.
- ▍Revenue PLN 22.0k
- ▍Operating income -PLN 729.0k
- ▍Net margin -2659.1%
Revenue PLN 148.0k; Operating income -PLN 678.0k.
- ▍Revenue PLN 148.0k
- ▍Operating income -PLN 678.0k
- ▍Net margin -408.1%
Revenue PLN 10.0k; Operating income -PLN 1.1M.
- ▍Revenue PLN 10.0k
- ▍Operating income -PLN 1.1M
- ▍Net margin 2440.0%
Revenue PLN 1.3M, +318,4% YoY; Operating income +937,7% YoY.
- ▍Revenue PLN 1.3M, +318,4% YoY
- ▍Operating income +937,7% YoY
- ▍Net income −910,6% YoY
- ▍Free cash flow −289,6% YoY
- ▍Net margin -1268.3%
Revenue PLN 15.2M, +53,2% YoY; Operating income +33,7% YoY.
- ▍Revenue PLN 15.2M, +53,2% YoY
- ▍Operating income +33,7% YoY
- ▍Net income +33,4% YoY
- ▍Free cash flow +33,8% YoY
- ▍Net margin -30.2%
Revenue PLN 9.9M; Operating income -PLN 6.0M.
- ▍Revenue PLN 9.9M
- ▍Operating income -PLN 6.0M
- ▍Net margin -69.4%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Pharmena SA Market data — financials · 2026-05-28
Ownership & reference
Insider activity
- Director · Common StockOther 685 @ $10,73$7K · 2026-07-31
- Director · Common StockOther 377 @ $10,73$4K · 2026-07-31
- Principal Accounting Officer · Common StockSold 1 247 @ $10,92$14K · 2026-07-16
- President, Network Solutions · Common StockOther 69 @ $10,76$742 · 2026-07-15
- Principal Accounting Officer · Common StockOther 937 @ $10,76$10K · 2026-07-15
- Director · Common StockSold 536 @ $10,70$6K · 2026-07-14
- Principal Accounting Officer · Common StockSold 1 371 @ $10,84$15K · 2026-07-06
- Principal Accounting Officer · Common StockOther 1 371 @ $8,75$12K · 2026-06-30
- General Counsel & Secretary · Common StockOther 1 265 @ $8,75$11K · 2026-06-30
- Director · Common StockSold 2 546 @ $9,53$24K · 2026-06-25
- Director · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
- Director · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
- Director · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
- Director · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
- Director · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
- Director · Common StockOther 19 290 @ $9,59$185K · 2026-06-24
- Principal Accounting Officer · Common StockOther 325 @ $8,77$3K · 2026-05-18
- Principal Accounting Officer · Common StockSold 431 @ $8,85$4K · 2026-05-18
- Director · Common StockOther 1 085 @ $9,21$10K · 2026-04-30
- Director · Common StockOther 1 085 @ $9,21$10K · 2026-04-30
- Director · Common StockOther 1 085 @ $9,21$10K · 2026-04-30
- General Counsel & Secretary · Common StockSold 6 176 @ $9,06$56K · 2026-04-20
- Principal Accounting Officer · Common StockSold 1 327 @ $9,28$12K · 2026-04-17
- President, Network Solutions · Common StockOther 229 @ $9,17$2K · 2026-04-16
- Principal Accounting Officer · Common StockSold 10 063 @ $9,08$91K · 2026-04-16
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2026-01-31 vs 2025-01-31): 164.2%Derived (calculated)
- Cash & equivalents (YoY) (2026-01-31 vs 2025-01-31): -12.3%Derived (calculated)
- EPS (diluted) (YoY) (2026-01-31 vs 2025-01-31): 103.9%Derived (calculated)
- EPS (basic) (YoY) (2026-01-31 vs 2025-01-31): 103.9%Derived (calculated)
- Total assets (YoY) (2026-01-31 vs 2025-01-31): 70.9%Derived (calculated)
- Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 27.3%Derived (calculated)
- Revenue (YoY) (2026-01-31 vs 2025-01-31): 14.5%Derived (calculated)
- R&D expense (YoY) (2026-01-31 vs 2025-01-31): 3.5%Derived (calculated)
- Operating income (YoY) (2026-01-31 vs 2025-01-31): 88.6%Derived (calculated)
- Operating cash flow (YoY) (2026-01-31 vs 2025-01-31): 143.4%Derived (calculated)
- Net margin (FY 2026-01-31): 0.5%Derived (calculated)
- Return on equity (FY 2026-01-31): 0.7%Derived (calculated)
- Return on assets (FY 2026-01-31): 0.3%Derived (calculated)
- Current ratio (FY 2026-01-31): 1.53xDerived (calculated)
- Debt-to-equity (FY 2026-01-31): 0.97xDerived (calculated)
- Net income (YoY) (2026-01-31 vs 2025-01-31): 103.9%Derived (calculated)
- Capex (YoY) (2026-01-31 vs 2025-01-31): 27.5%Derived (calculated)
- Long-term debt (YoY) (2026-01-31 vs 2025-01-31): 37.2%Derived (calculated)
- Revenue (annual): USD 480.59MSEC XBRL filing
- Current assets (annual): USD 279.84MSEC XBRL filing
- Pre-tax income (annual): USD -8.94MSEC XBRL filing
- Long-term debt (annual): USD 2.66MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
- Total assets (annual): USD 663.79MSEC XBRL filing